Design, synthesis and evaluation of nitric oxide-releasing derivatives of N-(n-butyl)matrinic acid and N-(n-butyl)matrinol as anti-hepatocellular carcinoma agents

Article abstract of DOI:10.3987/COM-14-13144

A series of novel furoxan-based derivatives of N-n-butyl matrinic acid (9a-m) and N-n-butyl matrinol (10a-m) were synthesized and their anti-human hepatocellular carcinoma (HCC) activities were evaluated. All derivatives displayed potential inhibition of

Full text of DOI:10.3987/COM-14-13144

HETEROCYCLES, Vol. 91, No. 2, 2015
301
HETEROCYCLES, Vol. 91, No. 2, 2015, pp. 301 - 312. © 2015 The Japan Institute of Heterocyclic Chemistry
Received, 4th December, 2014, Accepted, 9th January, 2015, Published online, 22nd January, 2015
DOI: 10.3987/COM-14-13144
DESIGN, SYNTHESIS AND EVALUATION OF NITRIC
OXIDE-RELEASING DERIVATIVES OF N-(n-BUTYL)MATRINIC ACID
AND N-(n-BUTYL)MATRINOL AS ANTI-HEPATOCELLULAR
CARCINOMA AGENTS
Ya-Xian Wu, Jun-Kai Huang, Lei-Lei Gao, Li-Qin He,* Peng Huang,* and
Xiao-Shan Wang
College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012,
China; E-mail: hlq661125@126.com, great7701@126.com
Abstract – A series of novel furoxan-based derivatives of N-n-butyl matrinic acid
(9a-m) and N-n-butyl matrinol (10a-m) were synthesized and their anti-human
hepatocellular carcinoma (HCC) activities were evaluated. All derivatives
displayed potential inhibition of HepG2 cell proliferation. Among these
derivatives, compounds 9a-f, 9j and 10b, 10g-i (IC50: 0.69−4.66 μM) were
superior to 5-FU (IC50: 5.82 μM). The further study showed that compounds 9a,
9c and 9f had higher antiproliferative activity on human hepatocellular carcinoma
cells Bel-7402 (IC50: 2.55-3.26 μM) and SMMC-7721 (IC50: 5.26-5.79 μM).
INTRODUCTION
Human hepatocellular carcinoma (HCC) is one of the most deadly cancers and has become the second
leading cause of death in China. Currently, there is no effective chemotherapy for HCC in humans in
clinic. Therefore, development of new therapeutic agents will be of great significance.1,2
Matrine (1) is one of the major quinolizidine alkaloids which derived from several traditional Chinese
medicinal herbs, including Sophora flavescens, Sophora and Sophora subprostrata.3-5 It has attracted
considerable attention because of its potential positive effects on human health and its broad biological
activities, such as anticancer, anti-inflammatory, analgesic, and notable antiviral effects. In China,
matrine has been used for the treatment of lipopolysaccharide-induced liver injury.6-9 However, up to now,
it has not been become an anticancer drug because of its moderate anti-tumor activities.10 Therefore, it is
significant to develop matrine derivatives with potential anticancer effects by structure modification.

302
HETEROCYCLES, Vol. 91, No. 2, 2015
Nitric oxide (NO), as a short-lived, highly diffusible, multifunctional messenger molecule, plays key role
in various physiological and pathological processes. Recently, it has been found that high concentration
of NO exhibited cytotoxic activity and could induce the apoptosis of tumor cells, prevent tumors from
metastasizing and assist macrophage to kill tumor cells.11,12 Indeed, NO-donating anti-cancer agents have
been investigated for their potential application for cancer therapy in clinic. For example, NO-aspirin has
entered clinical studies for the treatment of colorectal cancer.13 Furoxans is an important class of NO
donors, which can produce high concentration of NO and exhibit strong anti-cancer activity.14-17 Our
previous study indicated that NO-donating N-benzyl matrinic acid derivatives exhibited higher anticancer
activity than matrine and some are stronger than 5-FU.18 In view of above research results, we design and
synthesize two series of NO-donating N-n-butyl matrinic acid and N-n-butyl matrinol derivatives by using
N-alkyl group replacement N-benzyl, and then test their activity against human hepatocellular carcinoma
cells in vitro in order to find novel and more potential anti-cancer agents.
RESULTS AND DISCUSSION
The synthetic route of these target compounds is outlined in Scheme 1. The starting material matrine 1
was firstly reacted with sodium hydroxide, giving the hydrolytic ring-open derivative 2 as our previous
protocol.18 In the presence of potassium carbonate, 2 reacted with n-butyl bromide to gain compound 3,
which can produce 4 through hydrolysis with sodium hydroxide and offer 5 by reduction with lithium
aluminum hydride. Compound 6 was obtained by treatment 5 with succinic anhydride under the condition
of 4-N,N-dimethylaminopyridine (DMAP) in CH2Cl2. Finally, condensation of 4 and 6 with various
mono(phenylsulfonyl)furoxans 8a-m, were synthesized in a four-step sequence as previously described.18
Thus we got target compounds 9a-m and 10a-m. The structures of all target compounds were further
characterized by IR, MS and 1H NMR.
The antiproliferative activity of all target compounds against human HCC HepG2 cells was evaluated by
MTT assay,19 using 5-fluorouracil (5-FU) as control. All target compounds exhibited better activity
compared to matrine. Especially, 11 compounds (9a-h, 9k-l, 10b, 10d, 10e-g) displayed significant
activity which was superior to 5-FU. Furthermore, compounds 9a, 9c, and 9f exhibited optimal activity.
The IC50 of 9a (IC50 = 1.69 μmol/L), 9c (IC50 = 0.69 μmol/L) and 9f (IC50 = 0.94 μmol/L) against HCC
HepG2 cells was 3-8 fold than those of 5-FU (IC50 = 5.82 μmol/L) (Table 1). Compared with above
compounds (9a, 9c, 9f), the IC50 of N-benzyl derivatives was 2.16, 3.98 and 7.45 μmol/L against human
HCC HepG2 cells in the previous experiment. That is to say, the replacement of benzyl group to alkyl
group has better antiproliferative activity. Further test of these three compounds (9a, 9c, and 9f) for their
in vitro activity against human HCC Bel-7402 and SMMC-7721 cells were done by the same method as
described above, which revealed that these three compounds showed stronger toxicity activity than those

HETEROCYCLES, Vol. 91, No. 2, 2015
303
of matrine and 5-FU (Table 2). The results also indicated that the anti-proliferative effect of these three
compounds (IC50 = 2.32-5.79 μmol/L) on HCC Bel-7402 and SMMC-7721 was powerful than that of
5-FU (IC50 = 7.57-10.05 μmol/L). Therefore, we are interested in further studies to determine whether
those three compounds could become the candidates of anti-hepatocellular carcinoma agents.
O
C4H9-n
H
N
N
N
O
CO2H
b
O
a
N
N
N
2
3
1
C4H9-n
C4H9-n
SO2Ph
N
N
X
8a-m
g
CO2H
C
O
O
N
N
c
O
O
N
N
9a-m
4
C4H9-n
C4H9-n
O
C4H9-n
O
SO2Ph
O
N
OH
N
O
N
O
OH
X
8a-m
g
N
N
O
O
h
O
O
d
N
N
N
10a-m
5
6
SO2C6H5
HXO
e
8-10h
8-10i
8-10j
CCH2
X =OCH2C
8-10a
X= O(CH2)2
8-10b
X = O(CH2)3
N
SO2C6H5
C6H5O2S
N
X = OC2H4Ph-p
O
O
8-10c X = OCH(Me)CH2
N
8a-i
X = NH(CH2)2
N
O
O
X = O(CH )
2 4
8-10d
8-10e
X = NH(CH )
8-10k
8-10l
2 3
7
X = O(CH2)5
SO2C6H5
HXO
f
X = NHCH(Me)CH2
8-10f X = O(CH2)6
8-10g
N
N CH2CH2
N
X=
N
8-10m
O
X = O(CH2)2O(CH2)2
O
8j-m
Scheme 1. Reactions and reagents: (a) 1, NaOH (aq.), 100 °C, 2 h; 2, 20% H2SO4. (b) n-BuBr, DMF,
K2CO3, 60-70 °C, 5 h. (c) NaOH, EtOH, 0.5 h. (d) LiAlH4, THF, 1 h. (e) diols, 25%NaOH, THF, rt, 2 h.
(f) aminoalcohol, NaH, dry THF. (g) DMAP, EDCI, CH2Cl2. (h) succinic anhydride, DMAP, dry CH2Cl2,
reflux, 3 h.
Different activities of the tested compounds may be attributed to the different connecting arms. For
example, among the compounds 9a-9m, the compounds 9b and 9c whose connecting arm were diols, but
the compound 9c with branched chain spacers, was more active than the corresponding compound 9b
with liner chain spacers; on the other hand, the compounds 9k and 9l with aminoalcohols as connecting
arms showed the opposite effects: the compound 9k with liner chain spacers exhibited higher activity than
the compound 9l with branched chain spacers. Besides, for the compounds 10a-10m, the connecting arm
may be the most influential factor, for example, the anti-proliferative activities of 10b, 10d, 10e-g were
much better than that of 10j-m. The reason may be that, due to the introduction of the alkyl groups, the

304
HETEROCYCLES, Vol. 91, No. 2, 2015
hydrophobicity is increased and the molecular volume is expanded as well. Thus the anti-cancer activity
of these compounds is strengthened.
In summary, two series of furoxan-based derivatives of N-n-butyl matrinic acid (9a-m) and N-n-butyl
matrinol (10a-m) were synthesized, and their anti-proliferative activities in vitro were evaluated by MTT
assay. Preliminary screening indicated that all target compounds showed inhibition of HCC cells
proliferation. Moreover, 11 derivatives (9a-f, 9j and 10b, 10g-i) manifested better activity than 5-FU
against HCC cells. Particularly, compounds 9a, 9c and 9f exhibited a great potency superior to 5-FU in
cancer cells and deserved further investigation.
Table 1. The structures and anti-proliferative effects of HepG2 cells of the target compounds
Compound
X
IC50(μmol/L)a
1.69
Compound
10a
X
IC50(μmol/L)a
>20
O(CH2)2
O(CH2)3
OCH(Me)CH2
O(CH2)4
O(CH2)2
O(CH2)3
OCH(Me)CH2
O(CH2)4
9a
9b
9c
9d
9e
9f
2.87
0.69
3.19
3.06
4.66
>20
7.86
>20
10b
10c
10d
10e
O(CH2)5
O(CH2)6
O(CH2)5
O(CH2)6
0.94
>20
10f
O(CH2)2O(CH2)2
OH2CCCCH2
OC2H4Ph-p
HN(CH2)2
HN(CH2)3
HNCH2Me(CH)
7.26
>20
>20
4.43
5.85
>20
O(CH2)2O(CH2)2
OH2CCCCH2
OC2H4Ph-p
HN(CH2)2
HN(CH2)3
HNCH2Me(CH)
1.83
4.25
4.56
>20
>20
>20
9g
9h
9i
9j
9k
9l
10g
10h
10i
10j
10k
10l
>20
>20
9m
10m
Matrine
8069
5-FU
5.82
a IC50: a concentration required to inhibit tumor cell proliferation by 50 %. Data are expressed as the mean IC50 from the dose-response curves of at least three
independent experiments.
Table 2. The cytotoxicity (IC50, μmol/L) of 9a, 9c and 9f against HCC Bel-7402 and SMMC-7721 cell
liners.
In vitro cytotoxicity(IC50, μmol/L)
Compound
Bel-7402
2.55
SMMC-7721
5.79
9a
2.32
5.26
9c
3.26
5.76
9f
Matrine
1100
10081
5-FU
7.57
10.05
EXPERIMENTAL
1
Melting points were measured using a WRS-1B apparatus and were without any correction. H NMR
spectra were recorded on 400 MHz Bruker Avance DPX spectrometers and referenced with TMS as an
internal standard. All NMR spectra were recorded in CDCl3 at room temperature. IR spectra were

HETEROCYCLES, Vol. 91, No. 2, 2015
305
collected on Nicolet Avatar 6700 spectrometer using KBr film. ESI mass spectra were acquired using a
Thermo Fisher LTQ Orbitrap XL Liquid chromatography-mass spectrometry instrument. The
chromatograms were conducted on silica gel (100−200 mesh) and visualized under UV light at 254 and
365 nm. Compounds 8a-m were synthesized as previously described.18
4-(Decahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric acid (2). Matrine (1, 2.48 g, 0.01 mol)
was added to 10% NaOH aqueous solution (20 mL, 0.1 mol) and the mixture was stirred at 80 °C for 4 h.
The reaction mixture was cooled to room temperature and neutralized with 20% H2SO4, then concentrated
under reduced pressure to dryness. The residue was dissolved in MeOH and filtered. The filtrate was
concentrated under reduced pressure to dryness and yield 2 as white solid (2.23 g, 83.8%), mp
197.7-198.5 °C. ESI-MS m/z: 267.2306 [M+H]+ (Calcd for C15H27N2O2 267.2028); IR 3426, 2932, 2818,
1732 cm-1.
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric acid butyl ester (3). N-Butyl
bromide (4.3 ml, 0.04 mol), matrinic acid 2 (2.66 g, 0.01 mol) and K2CO3 (5.52 g, 0.04 mol) were added
to DMF (20 mL), and the resulting mixture was heated to 60-70 °C and stirred for 5 h. The reaction
solution was filtered to remove solids, the filtrate was dissolved in water (100 mL) and extracted with
EtOAc (20 mL) three times. The organic layer was washed with brine, dried over anhydrous Na2SO4, and
concentrated under reduced pressure. The residue was purified by chromatography to give 3 as light
yellow oil (2.81 g, 74.3%). ESI-MS m/z: 379.3564 [M+H]+ (Calcd for C23H43N2O2 379.3280); IR 2933,
2861, 2804, 2762, 1737 cm-1.
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric acid (4). Compound 3 (5.15 g,
13.6 mmol) was added to saturated NaOH-ethanol solution (40 mL). The mixture was stirred at 60 °C for
0.5 h. The reaction mixture was cooled to room temperature and neutralized with 20% H2SO4, then
concentrated under reduced pressure to dryness. The residue was dissolved in water and extracted with
EtOAc (20 mL). The water layer was concentrated under reduced pressure to dryness. The residue was
dissolved in MeOH and filtered. The filtrate was concentrated under reduced pressure to give 4 as light
white solid (4.08 g, 93.1%), mp 112.1-113.3 °C. ESI-MS m/z: 323.2684 [M+H]+ (Calcd for C19H35N2O2
323.2654); IR 3382, 2950, 2871, 1680 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.57 (m, 1H, OH), 3.64-3.40
(m, 2H, CH2), 2.57-2.40 (m, 10H, N-CH2, N-CH), 1.91 (m, 2H, CH), 1.86-1.62 (m, 2H, CH), 1.58-1.11
(m, 16H, CH2), 0.96-0.33 (t, 3H, CH3).
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butan-1-ol (5). Compound 3 (3.78 g, 0.01
mol) was added to dried THF (30 mL), then added LiAlH4 (0.76 g, 0.02 mol) at 0 °C. The resulting
mixture was stirred at room temperature for 1 h. The reaction mixture was added water dropwise at 0 °C
until no bubbles gave. After filtration, the filtrate was concentrated under reduced pressure. The residue
was dissolved in water (100 mL) and extracted with EtOAc (20 mL) three times. The organic layer was

306
HETEROCYCLES, Vol. 91, No. 2, 2015
washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to gain 5 as
light yellow oil (2.33g, 75.6%). ESI-MS m/z: 309.2892 [M+H]+ (Calcd for C19H37N2O 309.2861); IR
1
3396, 3324, 2927, 2855 cm-1; H NMR (400 MHz, CDCl3) δ 4.61 (s, 1H, OH), 3.57 (t, 2H, OCH2),
3.02-2.32 (m, 10H, N-CH2, N-CH), 1.96-1.21 (m, 18H, CH2, CH), 1.86-1.62 (m, 2H, CH), 0.91 (t, 3H,
CH3).
Succinic acid mono-[4-(2-butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyl] ester (6).
Compound 5 (3.08 g, 0.01 mol), succinic anhydride (2.0 g, 0.02 mol) and DMAP (1.22 g, 0.01 mol) were
added to a CH2Cl2 (20 mL), the mixture was stirred and refluxed for 5 h. After 5 h, the reaction mixture
was poured into water and neutralized with a saturated aqueous Na2CO3 solution. The aqueous mixture
was then extracted with CH2Cl2 (20 mL) three times. The organic layer was collected, dried (over
Na2SO4) and concentrated under reduced pressure to obtain 6 as light yellow oil (3.74 g, 91.7%). ESI-MS
m/z: 409.3106 [M+H]+ (Calcd for C23H41N2O4 409.3022).
General Procedure for the synthesis of 9a-m.
Compound 4 (84 mg, 0.26 mmol), DMAP (32 mg, 0.26 mmol), and 8a-m (0.17 mmol) were dissolved in
dry CH2Cl2 (6 mL), then added dropwise the solution of EDCI (50 mg, 0.26 mmol) in CH2Cl2 (2 mL) at
0 °C. The mixture was stirred at room temperature for 48 h. After 48 h, the reaction mixture was poured
into water and extracted with CH2Cl2. The organic layer was collected, dried (over Na2SO4) and
concentrated under reduced pressure. The residue was purified by TLC with 10:1 (v/v) CH2Cl2-MeOH.
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric
acid
2-(4-benzenesulfonyl-
furazan-3-yloxy)-ethyl ester (9a). The title compound was obtained starting from 8a and 4 (light yellow
oil, 54.3%). ESI-MS m/z: 591.2817 [M+H]+ (Calcd for C29H43N4O7S 591.2808); IR 2933, 2866, 2797,
1
2768, 2734, 1382, 1732, 1624, 1552, 1252, 1168 cm-1; H NMR (400 MHz, CDCl3) δ 0.85-0.90 (m, 3H,
CH3), 1.31~2.13 (m, 26H, CH, CH2), 2.34 (t, 2H, O=CCH2), 2.72 (t, 2H, N-CH2), 4.41-4.45 (t, 2H,
OCH2), 4.53~4.58 (t, 2H, OCH2), 7.56 (t, 2H, ArH), 7.70 (t, 1H, ArH), 7.99 (d, 2H, ArH).
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric
acid
3-(4-benzenesulfonyl-
furazan-3-yloxy)-propyl ester (9b). The title compound was obtained starting from 8b and 4 (light
yellow oil, 59.6%). ESI-MS m/z: 605.2984 [M+H]+ (Calcd for C30H45N4O7S 605.2964); IR 2935, 2877,
1
2777, 1384, 1732, 1616, 1554, 1448, 1264, 1169 cm-1; H NMR (400 MHz, CDCl3) δ 0.84-0.95 (m, 3H,
CH3), 1.30-2.15 (m, 28H, CH, CH2), 2.41 (t, 2H, O=CCH2), 2.74 (t, 2H, N-CH2), 4.11 (t, 2H, OCH2),
4.23 (t, 2H, OCH2), 7.58 (t, 2H, ArH), 7.71 (t, 1H, ArH), 8.03 (d, 2H, ArH).
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric
acid
2-(4-benzenesulfonyl-
furazan-3-yloxy)-1-methyl-ethyl ester (9c). The title compound was obtained starting from 8c and 4
(light yellow oil, 52.6%). ESI-MS m/z: 605.2981 [M+H]+ (Calcd for C30H45N4O7S 605.2964); IR 2936,
1
2877, 2812, 2769, 1385, 1733; 1617, 1556, 1449, 1254, 1169 cm-1; H NMR (400 MHz, CDCl3) δ

HETEROCYCLES, Vol. 91, No. 2, 2015
307
0.82-0.99 (m, 6H, CH3), 1.22-2.00 (m, 24H, CH, CH2), 2.40 (t, 2H, O=CCH2), 2.77 (t, 4H, N-CH2), 4.37
(d, 2H, OCH2), 4.50 (m, 1H, OCH), 7.63 (t, ArH), 7.77 (t, 1H, ArH), 8.05 (d, 2H, ArH).
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric
acid
4-(4-benzenesulfonyl-
furazan-3-yloxy)-butyl ester (9d). The title compound was obtained starting from 8d and 4 (light yellow
oil, 61.7%). ESI-MS m/z: 619.3139 [M+H]+ (Calcd for C31H47N4O7S 619.3121); IR 2927, 2853, 2797,
1361, 1732, 1625, 1554, 1448, 1168 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.91(t, 3H, CH3), 1.06-2.17 (m,
30H, CH, CH2), 2.42 (t, 2H, O=CCH2), 3.49-3.63 (t, 2H, N-CH2), 3.79 (t, 2H, OCH2), 3.96 (t, 2H, OCH2),
7.13-7.26 (t, 2H, ArH), 7.36 (t, 1H, ArH), 7.61 (d, 1H, ArH), 7.78 (d, 1H, ArH).
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric
acid
5-(4-benzenesulfonyl-
furazan-3-yloxy)-pentyl ester (9e). The title compound was obtained starting from 8e and 4 (light
yellow oil, 67.5%). ESI-MS m/z: 633.3292 [M+H]+ (Calcd for C32H49N4O7S 633.3277); IR 2933, 2864,
1
2767, 1384, 1731, 1615, 1553, 1449, 1169 cm-1; H NMR (400 MHz, CDCl3) δ 0.85 (t, 3H, CH3),
1.06-2.17 (m, 32H, CH, CH2), 2.53 (t, 2H, O=CCH2), 3.38-3.57 (t, 2H, N-CH2), 3.77 (t, 2H, OCH2), 3.88
(t, 2H, OCH2), 6.90-7.00 (m, 2H, ArH), 7.05(m, 1H, ArH), 7.51(d, 1H, ArH), 7.55(d, 1H, ArH).
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric
acid
6-(4-benzenesulfonyl-
furazan-3-yloxy)-hexyl ester (9f). The title compound was obtained starting from 8f and 4 (light yellow
oil, 61.4%). ESI-MS m/z: 647.3469 [M+H]+ (Calcd for C33H51N4O7S 647.3434); IR 2930, 2861, 1361,
1732, 1622, 1557, 1455, 1252, 1165 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.94 (t, 3H, CH3), 1.06-2.17 (m,
34H, CH, CH2), 2.37 (t, 2H, O=CCH2), 3.42-3.49 (t, 2H, N-CH2), 3.83 (t, 2H, OCH2), 4.01 (t, 2H, OCH2),
7.48(m, 2H, ArH), 7.53 (m, 1H, ArH), 7.97 (d, 2H, ArH).
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric acid 2-[2-(4-benzenesulfonyl-
furazan-3-yloxy)-ethoxy]-ethyl ester (9g). The title compound was obtained starting from 8g and 4
(light yellow oil, 54.1%). ESI-MS m/z: 635.3077 [M+H]+ (Calcd for C31H47N4O8S 635.3070); IR 2934,
1
2871, 1384, 1732, 1618, 1560, 1448, 1169 cm-1; H NMR (400 MHz, CDCl3) δ 0.87 (t, 3H, CH3),
0.94-2.67 (m, 30H, CH, CH2), 3.68-3.75 (m, 2H, OCH2), 3.76-3.83 (m, 2H, OCH2), 3.89-3.97 (m, 2H,
OCH2), 4.50-4.64(m, 2H, OCH2), 7.63 (t, 2H, ArH), 7.76 (t, J = 7.1 Hz, 1H, ArH), 8.01-8.14(d, 2H,
ArH).
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric
acid
4-(4-benzenesulfonyl-
furazan-3-yloxy)-but-2-ynyl ester (9h). The title compound was obtained starting from 8h and 4 (light
yellow oil, 52.5%). ESI-MS m/z: 615.2814 [M+H]+ (Calcd for C31H43N4O7S 615.2808); IR 2933, 2870,
1
2813, 2768, 1384, 2167, 1739, 1615, 1446, 1293, 1154 cm-1; H NMR (400 MHz, CDCl3) δ 0.89 (t, 3H,
CH3), 1.21-2.17 (m, 26H, CH, CH2), 2.37 (t, 2H, O=CCH2), 3.56 (t, 2H, N-CH2), 4.35(t, 2H, OCH2), 4.46
(t, 2H, OCH2), 7.31(m, 2H, ArH), 7.52(m, 1H, ArH), 7.64 (d, 1H, ArH), 7.96 (d, 1H, ArH).
4-(2-Butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyric acid 2-[4-(4-benzenesulfonyl-

308
HETEROCYCLES, Vol. 91, No. 2, 2015
furazan-3-yloxy)phenyl]-ethyl ester (9i). The title compound was obtained starting from 8i and 4 (light
yellow oil, 62.0%). ESI-MS m/z: 667.3128 [M+H]+ (Calcd for C35H47N4O7S 667.3121); IR 2929, 2875,
1382, 1732, 1615, 1505, 1446, 1165 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.95 (t, 3H, CH3), 1.23~2.09 (m,
26H, CH, CH2), 2.18 (t, 2H, O=CCH2), 2.73-2.83 (t, 2H, ArCH2), 2.96 (t, 2H, N-CH2), 4.29 (d, 2H,
OCH2), 7.24 (d, 2H, ArH), 7.28 (d, 2H, ArH), 7.66 (t, 2H, ArH), 7.80 (t, 1H, ArH), 8.11 (d, 2H, ArH).
N-[2-(4-Benzenesulfonylfurazan-3-yloxy)-ethyl]-4-(2-butyldecahydropyrido[3,2,1-ij][1,6]-
naphthyridin-1-yl)-butyramide (9j). The title compound was obtained starting from 8j and 4 (light
yellow oil, 44.4%). ESI-MS m/z: 590.2977 [M+H]+ (Calcd for C29H44N5O6S 590.2968); IR 3328, 2927,
1
2854, 1383, 1655, 1615, 1557, 1446, 1223, 1167 cm-1; H NMR (400 MHz, CDCl3) δ 0.98 (t, 3H, CH3),
1.05-1.93 (m, 28H, CH, CH2), 2.36 (t, 2H, NCH2), 3.69 (d, 2H, OCH2CH2), 4.18 (t, 2H, OCH2), 7.39 (d,
2H, ArH), 7.45 (d, 1H, ArH), 7.82-7.88 (t, 2H, ArH), 7.87-7.93 (t, 1H, NH).
N-[3-(4-Benzenesulfonylfurazan-3-yloxy)-propyl]-4-(2-butyldecahydropyrido[3,2,1-ij][1,6]-
naphthayridin-1-yl)-butyramide (9k). The title compound was obtained starting from 8k and 4 (light
yellow oil, 47.6%). ESI-MS m/z: 604.3133 [M+H]+ (Calcd for C30H46N5O6S 604.3124); IR 3333, 2932,
1
2864, 2766, 1372, 1651, 1620, 1553, 1447, 1354, 1168 cm-1; H NMR (400 MHz, CDCl3) δ 0.94 (t, 3H,
CH3), 1.23-1.98 (m, 30H, CH, CH2), 2.36 (t, 2H, NCH2), 3.23 (d, 2H, NHCH2), 4.06 (t, 2H, OCH2), 7.37
(d, 2H, ArH), 7.46 (d, 1H, ArH), 7.89~7.98 (t, 2H, ArH), 8.03 (t, 1H, NH).
N-[2-(4-Benzenesulfonylfurazan-3-yloxy)-1-methylethyl]-4-(2-butyldecahydropyrido[3,2,1-ij][1,6]-
naphthyridin-1-yl)-butyramide (9l). The title compound was obtained starting from 8l and 4 (light
yellow oil, 40.6%). ESI-MS m/z: 604.3160 [M+H]+ (Calcd for C30H46N5O6S 604.3124); IR 3299, 2928,
1
2860, 1357, 1668, 1615, 1545, 1446, 1292, 1169 cm-1; H NMR (400 MHz, CDCl3) δ 0.97 (t, 3H, CH3),
1.14-1.26 (d, 3H, CH3), 1.29-2.16 (m, 23H, CH,CH2), 2.34 (d, 3H, NCH, NCH2), 2.81 (t, 2H, NCH2),
2.96-3.09 (t, 2H, NCH2), 3.37-3.53 (d, 2H, OCH2), 3.67 (m, 1H, OCH), 7.34-7.40 (t, 2H, ArH), 7.62 (t,
1H, ArH), 7.74 (d, 1H, ArH), 7.82-7.88 (d, 1H, ArH), 8.08 (d, 1H, NH).
1-{4-[2-(4-Benzenesulfonylfurazan-3-yloxy)-ethyl]-piperazin-1-yl}-4-(2-butyldecahydropyrido-
[3,2,1-ij][1,6]naphthyridin-1-yl)-butan-1-one (9m). The title compound was obtained starting from 8m
and 4 (light yellow oil, 48.4%). ESI-MS m/z: 659.3588 [M+H]+ (Calcd for C33H51N6O6S 659.3546); IR
2927, 2855, 2807, 1382, 1655, 1446, 1291, 1240, 1151 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.89 (d, 3H,
CH3), 1.22-2.13 (m, 26H, CH, CH2), 2.51 (t, 4H, NH2), 2.77 (t, 6H, NH2), 3.63 (t, 4H, O=CNH2),
4.42-4.73 (t, 2H, OCH2), 7.44-7.49 (t, 2H, ArH), 7.63 (t, J = 7.8 Hz, 1H, ArH), 8.00 (d, 2H, ArH).
General Procedure for the Preparation of 10a-m.
Compound 6 (245 mg, 0. 6 mmol), DMAP (74 mg, 0.26 mmol), and 8a-m (0.5 mmol) were dissolved in
dry CH2Cl2 (8 mL), then added dropwise the solution of EDCI (117 mg, 0. 6 mmol) in CH2Cl2 (2 mL) at
0 °C. The mixture was stirred at room temperature for 48 h. The reaction mixture was poured into water

HETEROCYCLES, Vol. 91, No. 2, 2015
309
and extracted with CH2Cl2. The organic layer was collected, dried (over Na2SO4) and concentrated under
reduced pressure. The residue was purified by chromatography with 10:1 (v/v) CH2Cl2-MeOH.
Succinic acid 2-(4-benzenesulfonylfurazan-3-yloxy)-ethyl ester 4-(2-butyldecahydropyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)-butyl ester (10a). The title compound was obtained starting from 8a and 6
+
(colorless oil, 55.0%). ESI-MS m/z: 677.3204 [M+H] (Calcd for C33H49N4O9S 677.3176); IR 2931,
2860, 1735, 1618, 1560, 1449, 1169 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.94 (t, 3H, CH3), 1.21-2.09 (m,
30H, CH,CH2), 2.79 (t, 4H, O=CCH2), 4.09 (t, 2H, OCH2), 4.53 (d, 2H, OCH2), 4.63 (d, 2H, OCH2), 7.64
(t, 2H, ArH), 7.77 (t, 1H, ArH), 8.07 (d, 2H, ArH).
Succinic acid 3-(4-benzenesulfonylfurazan-3-yloxy)-propyl ester 4-(2-butyldecahydropyrido-
[3,2,1-ij][1,6]naphthyridin-1-yl)-butyl ester (10b). The title compound was obtained starting from 8b
and 6 (colorless oil, 57.4%). ESI-MS m/z: 691.3604 [M+H]+ (Calcd for C34H51N4O9S 691.3332); IR 2922,
1
2850, 1736, 1618, 1578, 1448, 1384; 1148 cm-1; H NMR (400 MHz, CDCl3) δ 0.97 (t, 3H, CH3),
1.24-2.03 (m, 32H, CH, CH2), 2.81 (t, 4H, O=CCH2), 4.07 (t, 2H, OCH2), 4.32 (t, 2H, OCH2), 4.53 (t, 2H,
OCH2), 7.65 (t, 2H, ArH), 7.78 (t, 1H, ArH), 8.08 (d, 2H, ArH).
Succinic acid 2-(4-benzenesulfonylfurazan-3-yloxy)-1-methyl-ethyl ester 4-(2-butyldecahydropyrido-
[3,2,1-ij][1,6]naphthyridin-1-yl)-butyl ester (10c). The title compound was obtained starting from 8c
and 6 (colorless oil, 54.8%). ESI-MS m/z: 691.3401 [M+H]+ (Calcd for C34H51N4O9S 691.3332); IR 2927,
2858, 1735, 1622, 1581, 1448, 1384, 1149 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.88-1.06 (m, 6H, CH3),
1.23-2.24 (m, 30H, CH, CH2), 2.57-2.79 (t, 4H, O=CCH2), 4.1 (t, 2H, OCH2), 4.23 (d, 2H, OCH2), 4.51
(m, 1H, OCH), 7.61 (t, ArH), 7.78 (t, 1H, ArH), 8.02 (d, 2H, ArH).
Succinic acid 4-(4-benzenesulfonylfurazan-3-yloxy)-butyl ester 4-(2-butyldecahydropyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)-butyl ester (10d). The title compound was obtained starting from 8d and 6
(colorless oil, 65.6%). ESI-MS m/z: 705.3522 [M+H]+ (Calcd for C35H53N4O9S 705.3489); IR: 2929,
2851, 1719, 1626, 1572, 1452, 1181 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.98 (t, 3H, CH3), 1.31-2.12 (m,
34H, CH, CH2), 2.81 (t, 4H, O=CCH2), 4.12 (t, 2H, OCH2), 4.20 (d, 2H, OCH2), 4.47 (d, 2H, OCH2),
7.65 (t, 2H, ArH), 7.78 (t, 1H, ArH), 8.07 (d, 2H, ArH).
Succinic acid 5-(4-benzenesulfonylfurazan-3-yloxy)-pentyl ester 4-(2-butyldecahydropyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)-butyl ester (10e). The title compound was obtained starting from 8e and 6
(colorless oil, 72.7%). ESI-MS m/z: 719.3703 [M+H]+ (Calcd for C36H55N4O9S 719.3645); IR 2929, 2857,
1735, 1618, 1553, 1449, 1169 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.88 (t, 3H, CH3), 1.32-2.10 (m, 36H,
CH, CH2), 2.62-2.79 (m, 4H, O=CCH2), 4.02-4.07 (t, 4H, OCH2), 4.36 (d, 2H, OCH2), 7.56 (t, 2H, ArH),
7.70 (t, 1H, ArH), 7.99 (d, 2H, ArH).
Succinic acid 6-(4-benzenesulfonylfurazan-3-yloxy)-hexyl ester 4-(2-butyldecahydropyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)-butyl ester (10f). The title compound was obtained starting from 8f and 6

310
HETEROCYCLES, Vol. 91, No. 2, 2015
(colorless oil, 62.3%). ESI-MS m/z: 733.3624 [M+H]+ (Calcd for C37H57N4O9S 733.3802); IR 2927, 2861,
1736, 1618, 1551, 1449, 1168 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.91 (t, 3H, CH3), 1.12-2.18 (m, 28H,
CH, CH2), 2.36-2.85 (m, 10H, N-CH, N-CH2), 2.79 (m, 4H, O=CCH2), 4.02 (t, 2H, OCH2), 4.24 (t, 4H,
OCH2), 7.55 (t, 2H, ArH), 7.71 (t, 1H, ArH), 7.99 (d, 2H, ArH).
Succinic acid 2-[2-(4-benzenesulfonylfurazan-3-yloxy)-ethoxy]ethyl ester 4-(2-butyldecahydro-
pyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyl ester (10g). The title compound was obtained starting
from 8g and 6 (colorless oil, 57.2%). ESI-MS m/z: 721.3470 [M+H]+ (Calcd for C35H53N4O10S
721.3438); IR 2939, 2869, 1735, 1615, 1549, 1448, 1161 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.98 (t, 3H,
CH3), 1.23-2.20 (m, 32H, CH, CH2), 3.77-3.83 (t, 4H, O=CCH2), 3.92 (t, 2H, OCH2), 4.10 (t, 2H, OCH2),
4.28 (d, 2H, OCH2), 4.57 (d, 2H, OCH2), 7.63 (t, 2H, ArH), 7.77 (t, 1H, ArH), 8.07 (d, 2H, ArH).
Succinic acid 4-(4-benzenesulfonylfurazan-3-yloxy)-but-2-ynyl ester 4-(2-butyldecahydropyrido-
[3,2,1-ij][1,6]naphthyridin-1-yl)-butyl ester (10h). The title compound was obtained starting from 8h
and 6 (colorless oil, 56.3%). ESI-MS m/z: 701.3211 [M+H]+ (Calcd for C35H19N4O9S 701.3176); IR 2927,
1
2850, 2163, 1736, 1618, 1550, 1449, 1280, 1168 cm-1; H NMR (400 MHz, CDCl3) δ 1.01 (t, 3H, CH3),
1.21-2.09 (m, 28H, CH, CH2), 2.37 (t, 2H, N-CH2), 2.67 (t, 4H, O=CCH2), 4.14 (t, 2H, OCH2), 4.78 (d,
2H, OCH2), 5.09 (d, 2H, OCH2), 7.66 (t, 2H, ArH), 7.80 (t, 1H, ArH), 8.10(d, 2H, ArH).
Succinic acid 2-[4-(4-benzenesulfonylfurazan-3-yloxy)-phenyl]-ethyl ester 4-(2-butyldecahydro-
pyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyl ester (10i). The title compound was obtained starting
from 8i and 6 (colorless oil, 52.2%). ESI-MS m/z: 753.2241 [M+H]+ (Calcd for C39H53N4O9S 753.3489);
IR 2926, 2850, 1734, 1617, 1551, 1169 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.86 (t, 3H, CH3), 1.21-2.26
(m, 28H, CH, CH2), 2.35(t, 2H, N-CH2), 2.69 (t, 4H, O=CCH2), 2.98 (t, 2H, Ar-CH2), 4.13 (d, 2H, OCH2),
4.30 (d, 2H, OCH2), 7.16-7.35 (m, 4H, ArH), 7.66 (t, 2H, ArH), 7.80 (t, 1H, ArH), 8.11 (d, 2H, ArH).
N-[2-(4-Benzenesulfonylfurazan-3-yloxy)-ethyl]-succinamic acid 4-(2-butyldecahydropyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)-butyl ester (10j). The title compound was obtained starting from 8j and 6
(colorless oil, 43.0%). ESI-MS m/z: 676.1356 [M+H]+ (Calcd for C33H50N5O8S 676.3335); IR 2918, 2848,
1698, 1556, 1504, 1457, 1168 cm-1; 1H NMR (400 MHz, CDCl3), δ 0.90 (t, 3H, CH3), 1.30-2.29 (m, 30H,
CH, CH2), 2.49-2.61 (t, 4H, O=CCH2), 3.51 (m, 2H, OCH2CH2), 4.07 (t, 2H, OCH2), 4.53 (d, 2H, OCH2),
7.64 (t, 2H, ArH), 7.75 (t, 1H, ArH), 8.06 (d, 2H, ArH), 8.09 (s, 1H, NH).
N-[3-(4-Benzenesulfonylfurazan-3-yloxy)-propyl]-succinamic acid 4-(2-butyldecahydropyrido[3,2,1-
ij][1,6]naphthyridin-1-yl)-butyl ester (10k). The title compound was obtained starting from 8k and 6
(colorless oil, 44.7%). ESI-MS m/z: 690.0312 [M+H]+ (Calcd for C34H52N5O8S 690.3492); IR 2934, 2867,
1648, 1618, 1560, 1448, 1283, 1169 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.01 (t, 3H, CH3), 1.30-2.29 (m,
32H, CH, CH2), 2.34-2.48 (t, 4H, O=CCH2), 3.55(m, 2H, NH-CH2), 4.09 (t, 2H, OCH2), 4.50 (d, 2H,
OCH2), 7.61 (t, 2H, ArH), 7.75(t, 1H, ArH), 8.02(d, 2H, ArH), 8.05(s, 1H, NH).

HETEROCYCLES, Vol. 91, No. 2, 2015
311
N-[2-(4-Benzenesulfonylfurazan-3-yloxy)-1-methyl-ethyl]-succinamic acid 4-(2-butyldecahydro-
pyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyl ester (10l). The title compound was obtained starting
from 8l and 6 (colorless oil, 44.9%). ESI-MS m/z: 690.0156 [M+H]+ (Calcd for C34H52N5O8S 690.3492);
1
IR 2926, 2859, 1649, 1618, 1554, 1448, 1281, 1168 cm-1; H NMR (400 MHz, CDCl3) δ 0.98 (t, 3H,
CH3), 1.31 (t, 3H, CH3), 1.40-2.29 (m, 28H, CH, CH2), 2.46 (t, 4H, O=CCH2), 3.23 (m, 2H, NHCH2),
4.09 (t, 2H, OCH2), 4.45 (d, 2H, OCH2), 7.64 (t, 2H, ArH), 7.76 (t, 1H, ArH), 8.01 (d, 2H, ArH), 8.06(s,
1H, NH).
4-{4-[2-(4-Benzenesulfonylfurazan-3-yloxy)-ethyl]-piperazin-1-yl}-4-oxo-butyric
acid
4-(2-
butyldecahydropyrido[3,2,1-ij][1,6]naphthyridin-1-yl)-butyl ester (10m). The title compound was
obtained starting from 8m and 6 (colorless oil, 55.8%). ESI-MS m/z: 745.3127 [M+H]+ (Calcd for
1
C37H57N6O8S 745.3914); IR 2930, 2861, 1648, 1618, 1553, 1449, 1290, 1169 cm-1; H NMR (400 MHz,
CDCl3), δ 0.95 (t, 3H, CH3), 1.23-2.12 (m, 30H, CH, CH2), 2.74-2.85 (t, 4H, O=CCH2), 2.86-2.94 (t, 4H,
N-CH2), 3.63 (t, 6H, N-CH2), 4.09 (t, 2H, OCH2), 4.56 (t, 2H, OCH2), 7.63 (t, 2H, ArH), 7.78 (t, 1H,
ArH), 8.06 (d, 2H, ArH).
Anticancer activity study (MTT assay)
Human HCC HepG2, Bel-7402, SMMC-7721 cells at 104 cells per well were cultured in 10% FBS
DMEM and a 37 °C incubator with 5% CO2 in 96-well flat-bottom microplates overnight. The cells were
incubated in triplicate with, or without, different concentrations of each test compound for 72 h. During
the last 4 h incubation, 30 μL of tetrazolium dye (MTT) solution (5 mg·mL-1) was added to each well.
The resulting MTT-formazan crystals were dissolved in 150 μL DMSO, and absorbance was measured
spectro-photometrically at 570 nm using an ELISA plate reader. The inhibition induced by each test
compound at the indicated concentrations was expressed as a percentage ((1 – the optical density ratio of
the treatment to vehicle control) × 100%). The IC50 value is calculated by Käber method as following:
IC50= Xm-I(P-(3-Pm-Pn)/4).
ACKNOWLEDGEMENTS
This study was supported by a grant from the Nature and Science Foundation of Department of Education,
Anhui province in China (No. KJ2010A204, KJ2013A168, KJ2014A134).
REFERENCES AND NOTES
1. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, Int. J. Cancer., 2001, 94, 153.
2. R. Siegel, D. Naishadham, and A. Jemal, CA: A Cancer Journal for Clinicians, 2013, 63, 11.
3. H. H. Wang and J. T. Cheng, Phytother. Res., 1994, 8, 70.
4. L. H. Zhang, Y. Huang, L. W. Wang, and P. G. Xiao, Phytother. Res., 1995, 9, 315.

312
HETEROCYCLES, Vol. 91, No. 2, 2015
5. S. Wang, G. Wang, X. Li, J. Sun, R. Ma, and L. Sheng, J. Chromatogr B: Analyt. Technol. Biomed.
Life Sci., 2005, 817, 319.
6. S. J. Zhang, J. P. Qi, L. B. Sun, B. Cheng, S. Pan, M. Zhou, and X. Sun, Mol. Biol. Rep., 2009, 36,
791.
7. J. Kamei, P. Xiao, M. Ohsawa, H. Kubo, K. Higashiyama, H. Takahashi, J. S. Li, H. Nagase, and S.
Ohmiya, Eur. J. Pharmacol., 1997, 337, 223.
8. X. D. Cheng, Y. Du, L. Huang, Z. M. Jing, and Z. G. Zheng, Chinese-German J. Clin. Oncol., 2008,
7, 213.
9. J. P. Zhang, M. Zhang, J. P. Zhou, F. T. Liu, B. Zhou, W. F. Xie, G. Cheng, C. Zhang, and D. H.
Qian, Acta Pharmacol. Sin., 2001, 22, 183.
10. L. S. Wang, Y. J. You, S. Q. Wang, X. Liu, B. M. Liu, J. N. Wang, X. Lin, M. S. Chen, G. Liang,
and H. Yang, Bioorg. Med. Chem. Lett., 2012, 22, 4100.
11. D. A. Wink, Y. Vodovotz, J. A. Cook, M. C. Krishna, S. Kim, D. Coffin, W. DeGraff, A. M. Deluca,
J. Liebmann, and J. B. Mitchell, Biochemistry (Moscow), 1998, 63, 802.
12. L. J. Hofseth, S. P. Hussain, G. N. Wogan, and C. C. Harris, Free Radical Biol. Med., 2003, 34, 955.
13. B. Rigas, Biochem. Soc. Trans., 2007, 35, 1364.
14. H. Cerecetto and W. Porcal, Med. Chem., 2005, 5, 57.
15. S. Moharram, A. H. Zhou, L. I. Wiebe, and E. E. Knaus, J. Med. Chem., 2004, 47, 1840.
16. D. Maksimovic-Ivanic, S. Mijatovic, L. Harhaji, D. Miljkovic, D. Dabideen, K. F. Cheng, K.
Mangano, G. Malaponte, Y. Al-Abed, M. Libra, G. Garotta, Ferdinando Nicoletti, and S.
Stosic-Grujicic, Mol. Cancer Ther., 2008, 7, 510.
17. M. Boiani, H. Cerecetto, M. González, M. Risso, C. Olea-Azar, O. E. Piro, E. E. Castella, A. L. de
Ceráin, O. Ezpeleta, and A. Monge-Vega, Eur. J. Med. Chem., 2001, 36, 771.
18. L. Q. He, J. Liu, D. K. Yin, and Y. H. Zhang, Chin. Chem. Lett., 2010, 21, 381.
19. C. S. Cheung, K. K. Chung, J. C. Lui, C. P. Lau, P. M. Hon, J. Y. W. Chan, K. P. Fung, and S. W. N.
Au, Cancer Lett., 2007, 253, 224.